MRNA
$73.76
Moderna
($2.04)
(2.69%)
MRNA
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.38)
Revenue:  N/A
Wednesday
Aug 5
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when MRNA reports earnings?
Beat
Meet
Miss

Where is MRNA's stock price going from here?
Up
Flat
Down
Stock chart of MRNA
Analysts
Summary of analysts' recommendations for MRNA
Score
Grade
Pivots
Resistance
$81.43
$79.46
$77.63

$75.66

Support
$73.83
$71.86
$70.03
Tweet
Growth
Description
Marina Biotech, Inc., formerly known as MDRNA, Inc., is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The Company's pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs in hepatocellular carcinoma and bladder cancer. Marina's goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Marina Biotech, Inc. is headquartered in Bothell, Washington.